Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2020 08:00 ET | Source: Novavax, Inc.

Novavax Appoints Biotechnology Veteran David Mott to Board of Directors

GAITHERSBURG, Md., June 16, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
June 15, 2020 10:09 ET | Source: Novavax, Inc.

Novavax to Raise $200 Million from Private Placement with RA Capital

GAITHERSBURG, Md., June 15, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
June 08, 2020 16:05 ET | Source: Novavax, Inc.

Novavax President of R&D Dr. Gregory Glenn to Discuss the Development of COVID-19 Vaccines on Panel at 2020 BIO Digital

GAITHERSBURG, Md., June 08, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
June 04, 2020 20:04 ET | Source: Novavax, Inc.

Novavax Awarded Department of Defense Contract for COVID-19 Vaccine

$60 million funding for manufacturing of NVX-CoV237310 million doses to be delivered to DoD in 2020 GAITHERSBURG, Md., June 04, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX), a late-stage...
May 27, 2020 08:00 ET | Source: Novavax, Inc.

Novavax Expands Large-Scale Global Manufacturing Capacity

Novavax acquires Praha Vaccines in Czech RepublicAnnual operating capacity of over 1 billion doses of COVID-19 vaccine antigen GAITHERSBURG, Md., May 27, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc....
May 25, 2020 16:30 ET | Source: Novavax, Inc.

Novavax Initiates Phase 1/2 Clinical Trial of COVID-19 Vaccine

First participants enrolled in Phase 1 portion of clinical trial of NVX‑CoV2373Preliminary immunogenicity and safety results expected in July 2020Phase 2 portion to begin promptly following successful...
May 11, 2020 16:05 ET | Source: Novavax, Inc.

Novavax Reports First Quarter 2020 Financial Results

CEPI increases investment up to $388 million for NVX‑CoV2373 vaccine development & manufacturingNVX‑CoV2373 Phase I trial initiating in May with preliminary results in JulyNanoFlu recently...
May 11, 2020 16:02 ET | Source: Novavax, Inc.

Novavax to Receive up to $388 Million Funding from CEPI for COVID-19 Vaccine Development and Manufacturing

Funds clinical development of NVX-CoV2373 through Phase 2Supports rapid scale-up of vaccine manufacturingAllows for increased production of Matrix-M adjuvantReserves global large-scale manufacturing...
May 11, 2020 11:52 ET | Source: Novavax, Inc.

Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series

GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...
May 06, 2020 09:15 ET | Source: Novavax, Inc.

Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 11, 2020

GAITHERSBURG, Md., May 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right